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Abstract: Optimal and safe control of drug delivery systems with continuous infusion protocol
is of key importance to avoid over-dosing or under-dosing of the patient. Advanced model based
control techniques are able to predict and regulate the amount of drugs given to the patient but
they rely heavily on patient model. This paper discusses and investigates the effects of synergistic
drug interaction between Propofol (hypnotic) and Remifentanil (opioid) and its requirements
on the robustness and stability of the closed loop system.
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1. INTRODUCTION
Individualised drug delivery systems during general anes-
thesia represent an important step forward in clinical
practice. The anesthesiologist has to provide specific care
during surgery or maintenance for the three main compo-
nents of general anesthesia (i.e. neuromuscular blockade,
hypnosis and analgesia) (Absalom et al. (2011); Struys
et al. (2003); Bailey and Haddad (2005)). In order to
achieve adequate levels of anesthesia the anesthesiologists
must adjust several parameters. An overview of the inputs
and the outputs of the anesthesia paradigm is depicted in
figure 1.
Fig. 1. Oversimplified overview of the anesthesia paradigm.
Nowadays, in clinical practice, open-loop systems such as
target controlled infusion systems are used. The open-loop
control strategies rise inaccuracies in drug delivery due to
the fact that they are based on generic population models
which obviously diverge from the real patient response.
The role of the anesthesiologist is to tackle this difference
by adequately changing the drug infusion rates. To ease
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the burden of this crucial role, a solution may be given by
introducing model based closed-loop control techniques.
These strategies are based on the availability of a pa-
tient model and then the role of the anesthetist will be
freed of some regular tasks so that he can focus more on
the state of the patient. From the patient-individualized
control point of view, pharmacodynamics models capture
the inter- and intra-patient variability and pose most
challenges for control (i.e. highly nonlinear characteristic)
(Schnider et al. (1998, 1999)). This is mainly due to the
nonlinearity introduced by the multiple drug interaction
model and significant unmeasurable disturbances present
in the system (noxious stimuli). A solution for optimal
control strategy of general anesthesia has not yet been
found. Closed-loop control strategies for depth of anesthe-
sia (DOA) regulatory systems are nowadays investigated
by several research groups worldwide, and a brief overview
is given below, within the physical limits of this paper.
Neuromuscular blockade (NMB) level is measured from
the electromyography signal obtained by electrical stimu-
lation. Control of NMB is done my means of continuous
infusion of a muscle relaxant. During the last two decades
several automatic control strategies for NMB have been
developed (Teixeira et al. (2014)).
Quantification of the hypnotic agent can be done by means
of availability of various indexes which are derived from
signals such as electroencephalogram (EEG). For instance,
bispectral (BIS) index is derived form EEG and it has been
shown to have a high sensitivity and specificity to measure
the drug effect (Struys et al. (2003)). Currently, BIS signal
is used as a reference for closed loop purposes (Ionescu
et al. (2008)).
The third component, i.e. analgesia, is still to be demys-
tified (Ionescu et al. (2014)). An accurate and objective
measurement of the patient’s response to analgesic drug
is still lacking. However, when BIS is known, a suitable
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interaction model between hypnotics and analgesics might
be helpful to simultaneously control both components of
depth of anesthesia.
Various interaction models between intravenous hypnotics
and analgesics have been described (Bouillon et al. (2004)).
Pharmacodynamic (PD) response surface models have
been developed to quantitatively describe the relationship
between two (or more) drug concentrations with their
corresponding combined clinical drug effect. Until now,
these interaction models have not been effectively used in
closed-loop control of depth of anesthesia.
The role of this paper is to illustrate the degree of
nonlinearity present in case of inter- or intra- patient
variability and how it affects the performance of the
closed loop system. For this purpose, we make use of
the PD model for synergy between Propofol (hypnotic
drug) and Remifentanil (opioid drug) and simulate various
situations. Closed loop control elements are enumerated
and motivated.
The structure of the paper is the following: Section 2
describes the hypnotic and opioid agents. In this section
the pharmacokinetic and pharmacodynamics of the two
drugs are presented. This is followed by Section 3 where
the interaction between the hypnotic and opioid agents
is analyzed. In this section some simulation results are
presented and discussed. Section 4 focuses on the control
problem in general anesthesia. In this section an overview
of the state of the art is presented and the importance of
drug interaction in developing an optimal control strategy
for general anesthesia is tackled.
2. HYPNOTIC AND OPIOID AGENTS
Before discussing the PD properties of the hypnotic and
opioid drug a schematic representation of a three compart-
mental model is presented in figure 2.
Fig. 2. A schematic representation of a three compartmen-
tal PK-PD model of the patient.
In this figure k12, k21, k13, k31, k1e represent the inter-
compartmental rate constants, k10 represents the clear-
ance rate from compartment 1. Concentrations in each
compartment are denoted by C1 - compartment 1, C2
- compartment 2, C3 - compartment 3, Ce - effect site
compartment.
During general anesthesia the patient receives a hypnotic
drug (eg. Propofol) to ensure loss of consciousness and
absence of post-operative recall of events occurred during
surgery. Additionally, the patient receives a dose of opioid
drug (eg Remifentanil) to ensure the absence of pain.
Some reasons why Remifentanil is increasingly used in
combination with Propofol in todays clinical practice are
listed below:
i) recently released sophisticated drug delivery systems
such as target-controlled infusion (Egan and Shafer
(2003)) allow for precise titration and safe administration
in patients with very narrow therapeutic margin;
ii) some new clinical applications are currently growing,
such as Remifentanils use as the sole agent for sedation
during painful procedures in patients breathing sponta-
neously, or as the analgesic component in intensive care
sedation;
iii) simultaneously, Remifentanil has permitted important
scientific research, leading to better understanding of post-
operative hyperalgesia and acute tolerance to the analgesic
action of opioids.
Remifentanil equilibration half-time between plasma and
the effect compartment has been modelled using continu-
ous EEG and is fast (0.1-1.5 min) (Glass et al. (1994)).
Transfer to central nervous system competes with distri-
bution processes and time to peak effect should be con-
sidered instead. During intravenous administration, the
PK properties of Propofol are characterized by an initial
distribution half-life of 2 - 8min, with the slow distribution
half-life ranging from 30 - 70 min. This depends on several
factors such as: method of administration (i.e. bolus or
infusion dosing) age, disease, body weight, gender, etc.
(Gepts et al. (1988); Shafer and Varvel (1991); Schnider
et al. (1998, 1999); Kirkpatrick et al. (1988)). These prop-
erties make these two drugs ideal candidates for continuous
infusion DOA regulatory systems.
Propofol concentration for loss of consciousness is reduced
by 25% in the presence of Remifentanil (i.e. 6 ng/ml)
(Nieuwenhuijs et al. (2003); Manyam et al. (2006); Al-
bertin et al. (2006); Bouillon et al. (2004); Kern et al.
(2004); Drover et al. (2004); Mertens et al. (2003); Fech-
ner et al. (2003)). Hence, a synergistic interaction with
hypnotics is present in the reaction of Remifentanil. The
minimal hypnotic concentration required to control nox-
ious stimuli is markedly reduced (50-60%) when a lower
concentration of opioid is added (Manyam et al. (2006)).
Intermediate opioid concentrations allow a further reduc-
tion in hypnotic requirement of 15-20%. The combina-
tion which allows the quickest recovery is shifted towards
high Remifentanil, low hypnotic concentrations. Typically,
Remifentanil concentrations must be above 8 ng/ml for
laryngoscopy or incision. This synergistic interaction is
also observed for the hypnotic effect, but is of a lower
magnitude. Without opioid, the hypnotic concentration
required for loss of consciousness is lower than the one
to prevent response to noxio us stimuli.
3. DRUG-INTERACTION ANALYSIS
In clinical practice the anesthesiologist takes advantage of
the synergy between drugs. One such advantage is given
by the fact that the therapeutic goals of the anesthetic
drugs can be achieved faster and with less toxicity. Another
advantage is that when combination of drugs is used, also a
faster recovery is achieved in comparison to the case when
individual drugs in higher doses are administered (?). The
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synergistic interaction between hypnotics and opioids is
characterized using response surface methodology (Minto
et al. (2000); Bouillon et al. (2004); Kern et al. (2004);
Manyam et al. (2006)). The response-surface approach
creates a three dimensional plot of the sedative and opioid
concentrations versus drug effect, quantitatively describing
the PD interaction of the two drugs.
The response-surface method serves as a scientific basis to
perform the analysis of the inter- and intra-patient vari-
ability. Combined with PK knowledge, the opioid-hypnotic
response surfaces may be used to establish the target
concentrations of the two drugs. In this way, an adequate
anesthesia level may be achieved and the recovery process
may be optimized (Minto and Schnider (2008)).
Clinical application of these drug interaction models
through the use of computer simulations constitutes a
revolutionary advance in understanding of anesthetic drug
clinical behavior. Clinical display systems incorporating
these response-surface drug interaction models are being
tested for real time use in the operating room as an ap-
proach to drug dosage optimization (Struys et al. (2003);
Johnson et al. (2008)).
Nowadays, response-surface models represents a strong
framework to guide the formulation of rational dosing
strategies. The response surface is navigated in the sense
that various points on the surface map are targeted at
different times during the anesthetic to achieve the goals
of the anesthetic. Response surface method has enabled
an in depth and clinically relevant understanding of the
marvelous synergy of sedatives and opioids when they are
administered together. It is this knowledge that can be
used now by the control engineers to exploit its benefits
for individualized drug dosing strategies (Ionescu et al.
(2014)).
Fig. 3. The relationship between opioid and hypnotic
drug concentrations and the probability of non-
responsiveness.
In presence of synergic drug interaction, a response surface
as in figure 3 is obtained. The X- and Y- axes of figure 3
are the normalized concentrations of opioid and hypnotic,
respectively. The Z axis of figure 3 is probability of non-
responsiveness. This surface has fundamental properties
of the opioid-hypnotic relationship. In this figure #1
represent no chance of non-responsiveness (this can be
because the patient is wide awake) while #2 represent
no chance of response. #3 shows the relationship between
the hypnotic drug and response when no opioid is given
to the patient, #4 shows the relationship between the
hypnotic drug and response when large doses of opioid
are given to the patient and #5 represent the maximum
synergy between the two drugs. The cross X denotes
the mean population values at 50% effect for Propofol
concentration C50P and for Remifentanil concentration
C50R, respectively.
A general interaction model for Remifentanil and Propofol
can be represented by the following equation (Kern et al.
(2004)):
E = Emax
(
CP
C50P
+ CRC50R + σ ∗ CPC50P ∗ CRC50R
)γ
1 +
(
CP
C50P
+ CRC50R + σ +
CP
C50P
+ CRC50R
)γ (1)
where: Emax represent the maximum effect of both drugs,
CP and CR are the Propofol and Remifentanil concentra-
tion in the effect compartment, C50P and C50R represent
the drug concentration for 50% of the maximum effect, γ
denotes patient’s sensitivity to the drugs and σ character-
izes the nature of the interaction between the two drugs.
In figures 4 and 5 the surface response of Propofol and
Remifentanil interaction but also the probability of non-
responsiveness are shown. Each patient has an individual-
ized response to drugs. Therefore, for each patient a dif-
ferent concentration of Propofol and respectively Remifen-
tanil is requested. Moreover, other important parameters
in characterizing interaction between two drugs are σ and
γ (ref. (1)).
In the remainder of this section, we illustrate the changes
in surface response when varying σ (figure 4) and γ (figure
5). In figure 4 the response surface when varying σ is
presented. In general, we have that the interaction:
for σ = 0, is additive
for σ < 0, is antagonistic and
for σ > 0, is synergic.
(2)
In figure 5 the influence of γ on patient’s sensitivity to the
drug effect is presented for synergistic case, the one valid
for combinations of Propofol and Remifetanil.
4. CLOSED-LOOP CONTROL OF ANESTHESIA
In the last decade, automated drug delivery systems have
become popular among researchers, due to enhanced need
for individualised drug delivery protocols and the enabling
role of control methodologies. The main functions of the
automation systems in anesthesia are monitoring and con-
trolling of the main variables (hypnosis, analgesia and
muscle relaxation). In the past, monitoring of the patient
during general anesthesia was performed by looking at
several signs such as: sweat, head lifting, movement, etc.
Nowadays, monitoring of general anesthesia has been con-
siderably improved. From the point of view of controlling
the main variables many efforts have been made in order
to provide the anesthetist with trustworthy techniques for
monitoring.
Current state of use in terms of target controlled in-
fusion combined with feedback control in drug delivery
systems is still based on averaged population models. In
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Fig. 4. Surface showing the interaction between hypnotic and opioid drug and the probability of non-responsiveness for
changes in σ. The values of σ used to show the changes in surface response are: σ=0.04 (top left), σ=0.5 (top right)
and σ=8 (bottom) and γ was fixed to 2.5.
Fig. 5. Surface showing the interaction between hypnotic and opioid drug and the probability of non-responsiveness for
changes in γ (γ=0.1 (top left), γ=1 (top right) and γ=10 (bottom) and σ was fixed at 0.2).
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anesthesia, several studies including classic and advanced
control strategies have been reported successfully (Dumont
(2014); Ionescu et al. (2011); Dumont et al. (2009); Rocha
et al. (2014); Ionescu et al. (2008); Krieger and Pistikopou-
los (2014); Ionescu et al. (2015)).
We will discuss here the model based adaptive closed loop
control principle, for this is the precursor of model based
predictive control drug delivery systems (see figure 6).
Fig. 6. Block diagram of a model-based adaptive closed-
loop system for automatic drug delivery.
The control system consists of four parts (figure 6):
1) the patient as the system to be controlled;
2) the response, which is considered as a measurable
representation of the process to be controlled;
3) a model of the input-output relationship
4) a controller.
To achieve adequate anesthesia anesthesiologists regularly
adjust the settings of several drug infusion devices as well
as the parameters of the breathing system to modify the
manipulated variables shown in figure 1. Several authors
have recognized the advantages associated with the use of
automatic controllers in anesthesia (Ionescu et al. (2008);
Absalom et al. (2011); Dumont et al. (2009); Dumont
(2014); Ionescu et al. (2011)) and they are briefly reviewed
below.
First, if the routine tasks are taken over by automatic con-
trollers, anesthesiologists are able to concentrate on critical
issues which may threaten the patient’s safety. Second, by
exploiting both accurate infusion devices and newly devel-
oped monitoring techniques, automatic controllers would
be able to provide drug administration profiles which may
avoid over-dosing and under-dosing. Moreover, they may
take advantage of the drug synergies, for which now a
proper modeling framework was developed (Minto et al.
(2000)). The ultimate advantage would be a reduction in
costs due to the reduced drug consumption and the shorter
time spent by the patient in the post anesthesia care unit.
Third, if enhanced with adaptation possibilties, initial ver-
sions of automated depth of anesthesia regulation systems
could provide individualised protocols if PD models were
to be adjusted to the actual patient instead of a population
based generic model parameters. Finally, if tuned properly,
automatic controllers may be able to compensate and
tailor the drug administration profile to the particular
stimulation intensity of each surgical procedure (Dumont
(2014); Absalom et al. (2011); Ionescu et al. (2015); Rocha
et al. (2014)).
As observed from the variations in the σ and the γ
parameter values, no unique controller will be able to
cope with all possible inter- and intra-patient variability
situations. Therefore, some sort of adaptation mechanism
of the PD model is of utmost necessity to achieve optimal
drug dosing profiles in an individualised DOA regulatory
system.
5. CONCLUSIONS
The interaction between analgesics and hypnotic is fun-
damental to understanding and defining the current anes-
thetic depth. If individualised DOA regulatory systems are
envisaged, one needs to take into account the effects of
inter- and intra-patient variability into account. This can
be done solely by introducing adaptation mechanisms into
the closed loop control strategy.
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